Home » Newsletters » BioWorld Science

BioWorld Science

April 26, 2018

View Archived Issues

FDA grants orphan drug designation to Lin's LBS-007

Mirati Therapeutics updates progress of key programs

Ono applies for manufacturing and marketing approval of encorafenib and binimetinib in Japan

ADC Therapeutics terminates its ADCT-502 program in HER2-expressing solid tumors

First patient dosed in phase IIb study of chikungunya VLP vaccine

FDA grants fast track designation to SYNB-1618

STRIVE trial results show promise for AVXS-101 in spinal muscular atrophy type 1 patients

FDA accepts for review sBLA for Fluzone Quadrivalent 0.5 mL for younger children

AbbVie submits BLA to the FDA for risankizumab in moderate to severe plaque psoriasis

Novel glucose transporter inhibitor SRI-37919 reduces glioblastoma cell growth

Chugai reviews highlights of first quarter 2018

Long-term exposure to ZYN-002 improves focal seizure frequency in epilepsy patients

Entasis Therapeutics and Zai Lab enter strategic development collaboration for ETX-2514

Phase IIb/III rheumatoid arthritis study of upadacitinib in Japanese patients meets primary endpoint

European Commission approves new dosing schedules for Opdivo

Sumitomo Dainippon Pharma, MMV enter joint research agreement

Phase III results presented for solriamfetol on excessive sleep in narcolepsy patients

Durect initiates patient dosing in phase IIa study of DUR-928 in alcoholic hepatitis

Maxinovel Pharmaceuticals presents the discovery of small-molecule PD-1/PD-L1 inhibitors

FDA grants fast track designation for ORP-101

Zealand holds end-of-phase II meeting with FDA on glepaglutide for short bowel syndrome

AveXis initiates phase III SPRINT trial of AVXS-101 in presymptomatic patients with SMA

Interim phase II results encouraging for tropifexor in primary biliary cirrhosis

Phase I/II results for DS-5141 in patients with DMD

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...